Earnings Preview — 1265 total
Quoin Pharmaceuticals heads into its May 7 earnings event with the lending market completely dried up — a structural tension that sits at the heart of the current setup. Every share available to borrow has been lent…
Arhaus heads into its May 7 Q1 results with a deteriorating analyst consensus and short sellers quietly rebuilding positions, as the stock hovers near multi-year lows. The analyst picture is uniformly cautious. Every…
YMAT enters tomorrow's earnings print with its borrow cost far above what a stock of its size would normally attract — a signal that the lending market has been unusually active around this micro-cap leisure products…
Crescent Energy heads into its Q1 2026 earnings report with options traders unusually bullish — a sharp contrast to short sellers who have been quietly covering for weeks. The options signal is the standout. The…
RDW's earnings tomorrow are almost incidental to the bigger story: its founding private equity sponsor has been aggressively exiting. AE Industrial Partners LP dumped more than 28 million shares over a ten-day stretch…
GXO Logistics walks into today's first-quarter earnings report nursing a 18% one-day loss and a 19% slide on the week — a brutal reset that now frames the entire print as a credibility test. The price action overwhelms…
CVRX reports Q1 2026 results on May 6 carrying fresh short-side momentum, a recent earnings track record of sharp declines, and a stock already down 13% over the past month. Short sellers have been adding positions…
AGL enters its Q1 2026 earnings release tomorrow with the sharpest analyst signal of the pre-print period arriving just hours ago: JP Morgan's Lisa Gill downgraded the stock to Underweight with a $21 target — a direct…
Design Therapeutics arrives at its May 8 Q2 earnings call on a genuine high. The stock jumped 23% on April 28 after Q1 EPS of -$0.29 beat estimates by $0.05 and the company narrowed its net loss. It has since pulled…
Coinbase Global reports Q1 2026 results on May 7 with short sellers firmly entrenched and options traders adding hedges into a stock that has already reclaimed a fifth of its value in a month. Short interest is the…
Valaris heads into its May 6 earnings release with a notable divergence between options traders turning more defensive and short sellers quietly reducing exposure. The clearest pre-earnings signal is in options. The…
AppLovin heads into its May 6 Q1 print with options sentiment at its most cautious in twelve months — a sharp contrast to a stock that has rallied hard. The options signal is the clearest tell in the setup. The…
Nuvation Bio heads into its May 8 earnings report with short sellers making a clear statement — and options traders ignoring them entirely. Short interest has become the dominant feature of the positioning picture. At…
CLNN heads into its May 8 earnings call riding an FDA-driven momentum spike — the most significant catalyst update in the company's recent history. The FDA news is the story. On May 4, Clene announced the agency…
Damora Therapeutics walks into its May 7 earnings report carrying two distinctly uncomfortable facts: a CFO who just stepped down and a short interest that has tripled in six weeks. The headline from Monday — CFO Lori…
BDSX reports Q1 2026 results on May 8 with the stock carrying a 25% monthly loss into the print — yet showing signs of near-term stabilisation. The price action tells a split story. Shares fell sharply through April to…
UTZ heads into its May 6 earnings report with short sellers rapidly unwinding what had been a materially elevated position — yet the analyst community remains firmly on edge. Short interest peaked at roughly 12.8% of…
Viatris heads into its May 7 Q1 earnings report with short sellers quietly adding exposure — even as the stock posts its best month in some time. The most notable positioning shift is in short interest. Bears have…
IAC Inc. heads into its Q1 2026 results today with a wave of upward analyst revisions at its back — and the clearest question is whether the fundamentals can validate the optimism. The analyst case for IAC has…
COMPASS Pathways reports Q1 2026 results on May 7 after a month that has completely re-priced the stock — and the short-side has scrambled to keep up. Options positioning has actually turned more bullish into the…
